Joost Verbeek

Joost’s research at the NKI will focus on bringing (cost)-effective innovations to the patient in an early stage of development by using decision-analytic models, identifying barriers and facilitators for implementation, and conducting scenario analyses. Moreover, he will investigate the role and impact of Coverage with Evidence Development (CED) programs on realizing this goal.

The treatments that will undergo (early) Health Technology Assessments conducted by Joost Verbeek as part of his PhD are high-dose chemotherapy with autologous stem cell transplantation for the treatment of metastatic breast cancer, hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with stomach cancer, and internet-based cognitive behavioural therapy for breast cancer survivors with treatment-induced menopausal symptoms.